This week in Other Barks & Bites: The Trump Administration’s Final Rule that would have required list prices of drugs to be displayed in television ads is blocked by the U.S. District Court for the District of D.C.; the STRONGER Patents Act is reintroduced into both houses of Congress; the leadership of the Senate IP Subcommittee releases a statement on the splintered Federal Circuit en banc denial in Athena; the U.S. Copyright Office designates the mechanical licensing collective; Huawei is the top earner of Chinese patents thus far in 2019; Intel enters a period of exclusive talks in its wireless patent auction; T-Mobile and Sprint extend their merger deadline; Amazon launches initiative to retrain 100,000 employees for high-tech positions; and major drugmakers ask the Supreme Court to take up a patent case involving functional claiming issues.
Business
- Groups on Both Sides Slam USTR Support for Delaying IP Waiver Extension Pending ITC Investigation
- USPTO Ramps Up Efforts to Promote Women Entrepreneurs
- Sign the Prenup: What Brands Can Learn From the Kanye West/Adidas IP Breakup
- Lessons from the Levandowski Case: Reimagining the Exit Interview as Risk Management
- Advocating for Ethics-Driven Regulation for Blockchain Technologies
Recent Posts
- What I’ll Be Watching for in the Amgen Oral Arguments
- A Dog’s Day in Court: Implications of the ‘Bad Spaniels’ Arguments on Parody Determinations and Noncommercial Use
- Other Barks & Bites for Friday, March 24: Non-DOCX Fee Delayed Further; SCOTUS Petition Says Hirshfeld’s Review of PTAB Decision Violated Federal Vacancies Reform Act; Moderna CEO Grilled by Senate Committee over COVID Vaccine Price Hike
- Bayh-Dole Opponents Slam-Dunked Once Again
- SCOTUS Skeptical that Bad Spaniels is Parody, But Questions Need to Overturn Rogers